NCT00395031View on ClinicalTrials.gov

Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Ziprasidone

Ziprasidone dose of between 40 mg po bid to 160 mg po bid for 8 weeks

Trial Locations (1)

10035

Manhattan Psychiatric Center, New York

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Manhattan Psychiatric Center

OTHER